Iodine[131I] Metuximab

To compare the efficacy and safety of combination iodine [¹³¹I] metuximab infusion and transcathether arterial chemoembolization (TACE) with those of TACE-alone for hepatocellular carcinoma (HCC).

PubMed, Cochrane Library, Embase, Web of Science, China Biology Medicine, China Science and Technology Journal Database, Wan Fang Data, and Chinese knowledge resource integrated databases were used for the literature search regarding controlled clinical trials comparing combination TACE and iodine [¹³¹I] metuximab infusion with TACE-alone for HCC treatment before February 1, 2016. The Jadad system evaluation method for research quality and RevMan 5.0 software were used for the meta-analysis.

In total, 1302 patients from 10 studies were included. The meta-analysis showed that the combination TACE and iodine [¹³¹I] metuximab infusion treatment for HCC was more effective than TACE alone, including 6-month survival (odds ratio [OR] = 2.05, 95% confidence interval [CI]: 1.41-2.98, P = 0.0002), 1-year survival (OR = 1.90, 95% CI: 1.41-2.55, P < 0.00001), and the total response rate (OR = 2.91, 95% CI: 2.08-4.07, P < 0.00001). Nine studies reported adverse reactions, mainly comprising poor appetite, nausea, vomiting, and abdominal discomfort. Fever, chills, and bone marrow suppression were more common in the combined treatment group, but abnormal liver function was not different between the two treatment groups. There was no report on serious complications or death directly related to either treatment.

Compared with TACE alone, the combination of TACE with iodine [¹³¹I] metuximab infusion for treating unresectable HCC may improve local efficacy and overall survival in these types of patients.

Objective: To evaluate the efficacy and adverse reactions of licartin with repeated administration in treatment of hepatocellular carcinoma (HCC) patients after liver transplantation. Methods: Clinical data of 60 patients after liver transplantation with licartin in Tianjin First Central Hospital from December 2012 to December 2016 were collected and analyzed.The patients were divided into A group(received single therapy, n=45)and B group(received repeated therapy with equal or greater than twice, n=15). The results of blood routine examination, liver function and thyroid function between the two groups(1 week before treatment, 2, 4 and 8 weeks after treatment) were compared. Survival time and adverse reactions were statistically analyzed. Results: There was no significant statistical difference on age, gender and AFP between the two groups(all P>0.05). Compared to baseline level 1 week before treatment, platelet levels were reduced 2 weeks after treatment, and gradually recovered to baseline level at 8 weeks(F=50.42 and 61.71, all P<0.05); 4 weeks after treatment, the alanine aminotransferase and total bilirubin levels were increased to a certain extent and recovered to baseline at 8 weeks(F=5.42 and 3.39, 8.95 and 6.84, all P<0.05). Thyroid function injury ratio for the two groups were 8.9% and 8.6%. No serious adverse reactions occurred, and mild adverse reactions could be tolerated with spontaneous remission or symptomatic treatment. There was no significant statistical difference between the two groups(χ²=0.459-1.0, all P>0.05). The median survival time was 34.0 months for A group, the 6-, 12-, 18-, 24-, 36- and 48-month overall survival rates for the two groups were 93.3%, 86.6%, 73.3%, 62.2%, 48.9%, 33.3% and 100%, 93.3%, 86.7%, 80.0%, 66.7%, 66.7%, respectively (χ²=4.324, P=0.038). HCC in situ recurrence rate for the two groups were 15.6% and 13.3%(χ²=1.0, P=0.601). The incidence of hepatocellular metastasis for the two groups were 22.2% and 20.0%(χ²=1.0, P=0.585). Conclusion: Repeated licartin administration could prevent HCC recurrence and prolong survival with satisfactory safety.